Targeting RAGE: A Novel Therapeutic Strategy Against AGE-Mediated PCa Progression
Overview
Purpose: The accumulation of advanced glycation end products (AGEs) and their interaction with the receptor for AGEs (RAGE) have been implicated in the progression of prostate cancer (PCa), the second most diagnosed cancer in men worldwide. However, therapeutic strategies targeting RAGE remain underexplored, representing a critical gap in current cancer treatment approaches. This study aimed to investigate the role of the AGE-RAGE signaling pathway in PCa progression, focusing on how RAGE inhibition affects cell migration and how RAGE knockdown influences both migration and proliferation. Methods: RAGE inhibition was achieved using TTP-488 in DU145 cells, and a migration assay assessed cell migration in response to the following treatments: no treatment (NT), the negative control; AGEs, the positive control; TTP-488; and AGEs & TTP-488. RAGE knockdown was performed via shRNA transfection in LNCaP cells, confirmed by Western Blot analysis. A Trypan Blue Proliferation assay evaluated cell growth in LNCaP shRAGE and shControl cells, while a migration assay determined migration in those cells. It was hypothesized that RAGE inhibition and knockdown would reduce PCa cell migration, with knockdown specifically reducing proliferation. Results: ANOVA and post-hoc analyses revealed that disrupting AGE-RAGE signaling via inhibition and genetic knockdown effectively mitigates cell migration, with knockdown also significantly hindering cell proliferation. These findings support the research hypothesis. Conclusion: Targeting RAGE in PCa reveals a transformative therapeutic approach to control tumor progression and metastasis, set to redefine cancer treatment globally. Future studies should explore combining RAGE disruption with conventional treatments like chemotherapy.
Competition history
- AJAS 2026
Related projects
JSHS · 2025
Targeting RAGE: A Novel Therapeutic Strategy Against AGE-Mediated Prostate Cancer Progression
ISEF · 2025
Assessing Novel RIPK2-MKK7 Interaction Inhibitors in Prostate Cancer Cell Lines
CSEF · 2008
The Inhibitory Effect of HKa on Prostate Cancer Line DU145 Is Mediated by Blocking Metastasis
CSEF · 2014
Break the AGE Barrier! Inhibit Advanced Glycation End-products to Combat Atherosclerosis, Cancer and Diabetic Disorders
CSEF · 2015
Identification of NUSAP1 as a Novel Therapeutic Target for Aggressive Prostate Cancer
JSHS · 2025
Machine learning optimized in silico design of a de novo RAGE inhibitor: a small molecule approach to slowing the progression of inflammatory disease
ISEF · 2025
Machine learning optimized in silico design of a de novo RAGE inhibitor: a small molecule approach to slowing the progression of inflammatory disease
CSEF · 2009
Further Investigation of the Inhibitory Effect of HKa on Metastasis of Prostate Cancer Cell Line DU145
Closest projects by meaning, across every fair and year in the corpus.
Browse more like this
Source: AAAS Annual Meeting (Confex) / American Junior Academy of Science